Introduction
Emerging resistance in common pathogenic members of the Enterobacterales is a world-wide phenomenon and presents therapeutic problems for practitioners, both in the community and in hospital practice. The Australian Group on Antimicrobial Resistance (AGAR) commenced surveillance of the key Gram-negative pathogens, Escherichia coli and Klebsiella species in 1992. Surveys have been conducted biennially until 2008 when annual surveys commenced, alternating between community-and hospitalonset infections (http://www.agargroup.org/sur-veys). In 2004, another genus of Gram-negative pathogens in which resistance can be of clinical importance, Enterobacter species, was added. E. coli is the most common cause of communityonset urinary tract infection; Klebsiella species are less common but are known to harbour important resistances. Enterobacter species are less common in the community, but of high importance due to intrinsic resistance to firstline antimicrobials in the community. Taken together, the three groups of species surveyed are considered to be valuable sentinels for multiresistance and emerging resistance in enteric Gram-negative bacilli. In 2013 AGAR com-menced the Enterobacteriaceae Sepsis Outcome Programme (EnSOP) which focused on the collection of resistance and some demographic data on all isolates prospectively from patients with bacteraemia. In 2015, Pseudomonas aeruginosa and Acinetobacter species were added, and the program referred to as the Gram-negative Sepsis Outcome Program (GNSOP).
Resistances of particular interest include resistance to ß-lactams due to ß-lactamases, especially extended-spectrum ß-lactamases, which inactivate the third-generation cephalosporins that are normally considered reserve antimicrobials. Other resistances of interest are to agents important for treatment of these serious infections, such as gentamicin; and resistance to reserve agents such as ciprofloxacin, meropenem and colistin.
The objectives of the 2017 surveillance program were to: 
Species identification
Isolates were identified using the routine method for each institution; Vitek ® , Phoenix™ Automated Microbiology System, or where available mass spectrometry (MALDI-ToF).
Susceptibility testing
Testing was performed by two commercial semi-automated methods, Vitek 2 (BioMérieux, France) or Phoenix (Becton Dickinson, USA), which are calibrated to the ISO reference standard method of broth microdilution. Commercially available Vitek AST-N246 and AST-N247, or Phoenix NMIC-203 and NIMC-404 cards were utilized by all participants throughout the survey period. The CLSI M100 1 and EUCAST v8.0 2 breakpoints from January 2018 have been employed in the analysis. For analysis of cefazolin, breakpoints of ≤4 mg/L for susceptible, ≥ 8 mg/L for resistant were applied due to the restricted minimum inhibitory concentration (MIC) range available on the commercial cards, recognising that the January 2018 breakpoint is actually susceptible ≤2 mg/L. All referred isolates were screened using realtime polymerase chain reaction (PCR) platform (LC-480) and published primers for the presence of bla TEM and bla SHV , CTX-M-type genes (groups 1, 2, 9, 8/25), plasmid-borne AmpC (bla CIT , bla DHA , bla EBC , bla ACC , bla FOX , bla MOX ), and carbapenemases genes (bla IMP , bla NDM , bla KPC , bla OXA-48-like , bla VIM , bla GES , bla SME , bla IMI ). [3] [4] [5] PCRs was also used to detect bla IMP types, known plasmid-mediated quinolone resistance mechanisms (qnr, efflux [qepA, oqxAB] and aac (6')-Ib-cr), aminoglycoside ribosomal methyltransferases (armA, rmtB, rmtC, rmtF), and mobile colistin resistance genes (mcr-1, mcr-2, mcr-3). [6] [7] [8] [9] [10] [11] All referred E. coli were examined for membership of the O25b-ST131 clone. 12 All isolates with demonstrated carbapenemase activity and any amikacin resistant isolates were also screened for OXA-23-like, -24, and -58 carbapenemases. 13 All isolates with carbapenemase activity were subjected to whole genome sequencing using the Illumina MiSeq platform. Data were analysed using the Nullarbor bioinformatic pipeline. 14 The pipeline was used to identify the multi-locus sequence type and the resistome.
Molecular confirmation of resistances

Results
The species isolated, and the numbers of each are listed in Table 1 
Escherichia coli
Moderately high levels of resistance to ampicillin (and therefore amoxicillin) were maintained (53.0%/54.4%, CLSI/EUCAST criteria), with c For EUCAST interpretation, the clavulanate is fixed at 2 mg/L, rather than a 2:1 ratio used in CLSI guidelines. As all susceptibility test cards used have a 2:1 ratio of clavulanate no EUCAST category has been applied. Most of the E. coli strains with ESBL genes harboured genes of the CTX-M type (408/536 = 76%). Fifty-three percent of E. coli with CTX-M group 1 types were found to belong to sequence type 131 (O25b-ST131). ST131 accounted for 57% of E. coli ESBL phenotypes that were ciprofloxacin resistant (MIC >1 mg/L), and only 5% of ciprofloxacin susceptible ESBL phenotypes.
Table 3. Multiple acquired resistances by species, 2017
Number of acquired resistances (EUCAST breakpoints)
Non-multi-resistant
Multi-resistant
Species
Klebsiella pneumoniae
K. pneumoniae showed slightly higher levels of resistance to piperacillin-tazobactam compared with E. coli, but lower rates of resistance to amoxicillinclavulanic acid, cefazolin, ceftriaxone, ceftazidime, ciprofloxacin, gentamicin, and trimethoprimsulfamethoxazole. Ten (1.0%) K. pneumoniae isolates had elevated meropenem MICs (see below). ESBLs were present in 77 of 95 (81%) presumptively ESBL-positive isolates of K. pneumoniae, 67 (87%) of which were confirmed to be of the CTX-M type. 
Enterobacter cloacae complex
Discussion
AGAR has been tracking resistance in sentinel enteric Gram-negative bacteria since 1992. From 2008, surveillance was segregated into hospitalversus community-onset infections. The last year of hospital-onset only surveillance was 2011. 15 In 2013, the first survey of antimicrobial resistance among Enterobacterales isolates from bacteraemic patients through Australia was conducted using an approach similar to that conducted by the European EARS-Net program. 2017 was the fifth survey of antimicrobial resistance among Enterobacterales, and the third for P. aeruginosa and Acinetobacter spp. from bacteraemic patients through Australia.
CTX-M-producing E. coli and Klebsiella species and gentamicin-and ciprofloxacin-resistant E. coli continued to be a problem in patients with bacteraemia. Of concern is the high proportion of E. coli that belong to the O25b-ST131 clone. Carbapenem resistance attributable to acquired carbapenemases are still uncommon in patients with bacteraemia in Australia, although seven different types (IMP, KPC, NDM, OXA-181, OXA-23, VIM, and GES) were detected from thirteen of the participating institutions. Compared with many other countries in our region, resistance rates in Australian Gram-negative bacteria are still relatively low, 16 but similar to those observed in 2017 in many Western European countries. 17 Multi-resistance is being increasingly observed, especially in E. coli and E. cloacae complex, both of which have multi-resistance rates (as defined by AGAR) above 18%. This is likely to drive more broad-spectrum antibiotic use, and increase the resistance selection pressure for important reserve classes, especially the carbapenemases.
